AREG mediates transient hepatocellular carcinoma resistance to receptor tyrosine kinase inhibitors
Lou et al. define the multiple-stage evolutionary trajectory of lenvatinib resistance in hepatocellular carcinoma cell models and identify a transient NF-κB-AREG-EGFR signaling axis that supports early resistance.